Collis Williams


Adapalene, the active ingredient in Differin? Gel/Cream, is an entirely new chemical entity that possesses some biologic activities of tretinoin, but has distinct physiochemical properties. Biochemical and pharmacological profile studies have demonstrated that adapalene is a potent modulator of cellular differentiation, keratinization and inflammatory processes, all of which represent important features in the pathology of acne vulgaris. Mechanistically, adapalene binds to specific retinoic acid nuclear receptors but, unlike tretinoin, does not bind to the cytosolic receptor protein. This difference may explain the reduced irritation seen with adapalene compared to tretinoin.

Although the exact mode of action of adapalene is unknown, current evidence suggests that topical adapalene – Differin? – normalizes the differentiation of follicular epithelial cells, resulting in decreased micro-comedone formation. Clinical studies have shown that topical adapalene is effective in reducing the noninflammatory lesions, such as whiteheads and blackheads, and moreover suggests that the topical application of this new molecule successfully reduces the inflammatory components of acne such as papules and pustules.

Galderma, a global pharmaceutical company, focuses exclusively on dermatology, specializing in topical prescription products to treat a number of pathologies including acne, eczema and rosacea. Anti-acne products constitute the Company’s most extensive line, as a result of Galderma’s leadership in research on retinoids. The company holds more than 500 patents worldwide, representing one of the most comprehensive range of products for the treatment of dermatological diseases.

Further Differin? information: Collis Williams Ltd. Tel: 21 22 41 04, 21 24 48 47